Skip to main content
KOREA ARLICO PHARM CO.,LTD. logo

KOREA ARLICO PHARM CO.,LTD. — Investor Relations & Filings

Ticker · 260660 ISIN · KR7260660006 KO Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2026-03-27 Declaration of Voting R…
Country KR South Korea
Listing KO 260660

About KOREA ARLICO PHARM CO.,LTD.

https://jazzarlico.tradekorea.com/compa…

Korea Arlico Pharm Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes prescription (ETC) and over-the-counter (OTC) drugs, medical devices, and oriental medical preparations, with a specialization in generic pharmaceuticals. Operating from a KGMP-certified facility, it focuses on continuous innovation to improve human health. The company serves its domestic market and exports its products to numerous countries, with the goal of expanding its global presence.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Regular Shareholders’ Meeting Results) and provides detailed AGM voting results, resolution approvals, dividend decisions, and related voting percentages. This corresponds to an official declaration of shareholder vote outcomes at a general meeting. Therefore, it matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory submission reporting the appointment, reappointment, and dismissal of outside directors (“사외이사”) for 알리코제약(주). It provides detailed information on changes to the board composition, including names, appointments dates, terms, and professional backgrounds of the outside directors. This clearly falls under announcements of changes in the company’s board of directors, matching the “Board/Management Information” category.
2026-03-27 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Allico Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2025. It includes the independent auditor's report from Samil PricewaterhouseCoopers, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This document is a standalone audit report and financial statement package, which fits the 'Audit Report / Information' (AR) category. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from Alco Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data (assets, liabilities, revenue, profit/loss), and auditor information (Samil PwC). While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the completion and submission of the audit report to the regulator, rather than the full annual report document itself. Therefore, it is classified as an Audit Report / Information document. FY 2025
2026-03-19 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a '주주총회소집공고' (Notice of General Meeting of Shareholders) for Allico Pharmaceutical. It contains detailed agenda items, director candidate information, governance changes, and proxy solicitation details. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on matters at the upcoming meeting.
2026-03-03 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by Allico Pharmaceutical Co., Ltd. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including agenda items (amendment of articles, election of directors, approval of financial statements), proxy solicitation details, and candidate information. It is a formal regulatory filing intended to solicit shareholder votes for the meeting.
2026-03-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.